Abstract
Monoclonal antibodies inhibiting calcitonin gene related peptide (CGRP) or its receptor have been widely used for migraine prophylactic therapy for the past three years. Evaluation of their efficacy and safety of therapy in real clinical practice is needed.Objective: to evaluate the efficacy and safety of Erenumab, a monoclonal antibody inhibiting the CGRP receptor during three months of therapy.Patients and methods. Sixty-eight patients (58 women and 10 men, mean age 37±10.4 years) with episodic or chronic migraine who were treated with Erenumab were observed. Patients were assessed with MIDAS, WPAI, and HADS scales; the presence of cutaneous allodynia was evaluated with ASC-12 questionnaire. Patients kept a headache diary and marked adverse events during the whole treatment period.Results and discussion. 47 patients (69%) had chronic migraine and 32 (71.9%) had medication overuse headache. In 48 patients (70%) after 3 injections of Erenumab the number of days with migraine decreased by 50% or more. In 7 patients (10%), the reduction in headache days was more than 75%; 20 (29%) did not experience sufficient effect after three months of therapy. Nineteen adverse events were noted in 15 (22%) patients. Severe constipation led to discontinuation of treatment in two patients (3%).Conclusion. The study showed the efficacy and safety of Erenumab for migraine prophylaxis in both patients with episodic and chronic migraine.
Highlights
Monoclonal antibodies inhibiting calcitonin gene related peptide (CGRP) or its receptor have been widely used for migraine prophylactic therapy for the past three years
Sixty-eight patients (58 women and 10 men, mean age 37±10.4 years) with episodic or chronic migraine who were treated with Erenumab were observed
Patients were assessed with MIDAS, WPAI, and HADS scales; the presence of cutaneous allodynia was evaluated with ASC-12 questionnaire
Summary
Клиническая эффективность и безопасность анти-CGRP(r) моноклональных антител в реальной клинической практике после трех месяцев терапии. В проведенном исследовании были отмечены эффективность и безопасность эренумаба для профилактики мигрени у пациентов как с эпизодической, так и с хронической мигренью. При частых (>4 дней с головной болью в месяц) или тяжелых приступах мигрени, а также при хронической мигрени показана профилактическая терапия. В связи с этим целью нашего исследования было оценить эффективность и безопасность применения эренумаба в реальной клинической практике, а также привести характеристики пациентов с мигренью, которые получают терапию эренумабом. Нами было проведено обсервационное когортное проспективное исследование, в которое вошли все пациенты с мигренью, которые в качестве профилактической терапии мигрени применяли анти-CGRP(r) мАТ (эренумаб) в специализированной Клинике головной боли. Среднее количество дней с головной болью мат), блокатор рецепторов ангиотензина II типа (кандесарв месяц в группе эпизодической мигрени составляло тан) и инъекции ботулотоксина типа А
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
